2022
Comparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia
Pettigrew MM, Kwon J, Gent JF, Kong Y, Wade M, Williams DJ, Creech CB, Evans S, Pan Q, Walter EB, Martin JM, Gerber JS, Newland JG, Hofto ME, Staat MA, Fowler VG, Chambers HF, Huskins WC. Comparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia. MBio 2022, 13: e00195-22. PMID: 35323040, PMCID: PMC9040816, DOI: 10.1128/mbio.00195-22.Peer-Reviewed Original ResearchConceptsCommunity-acquired pneumoniaShort-course strategyBeta-lactam therapyTreatment strategiesAntibiotic useRespiratory microbiomePediatric community-acquired pneumoniaDays of antibioticsShorter antibiotic coursesStandard-strategy groupDays of therapyStandard treatment strategyAntibiotic resistanceAdditional rationaleEffectiveness of interventionsImpact of durationAntibiotic coursesThroat swabsCourse strategyAntibiotic treatmentPediatric pneumoniaCourse treatmentLow prevalencePneumoniaAntibiotic resistance determinants
2020
175. Randomized Double-blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP)
Williams D, Creech C, Walter E, Martin J, Gerber J, Newland J, Howard L, Hofto M, Staat M, Oler R, Conrad T, Tuyishimire B, Pettigrew M, Fowler V, Chambers H, Zaoutis T, Evans S, Huskins W. 175. Randomized Double-blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP). Open Forum Infectious Diseases 2020, 7: s216-s216. PMCID: PMC7776421, DOI: 10.1093/ofid/ofaa439.485.Peer-Reviewed Original ResearchShort-course therapyCourse therapyAntibiotic exposureClinical improvementOutpatient therapyAdverse effectsDouble-blind Controlled TrialPlacebo-controlled superiority trialDays of antibioticsInitial clinical improvementShort antibiotic exposureShorter antibiotic coursesCommunity-Acquired PneumoniaStart of therapyCAP treatmentChildren ages 6Antibiotic coursesInitial therapyAcquired PneumoniaBaseline characteristicsClinical responseSecondary outcomesStandard therapyControlled TrialsPrimary outcome